Surrozen is focused on developing uniquely-engineered antibodies that replicate the function of Wnt pathway proteins to help repair tissue damaged by disease. We are able to generate specific pharmacological tools for research and discovery of therapeutics to promote disease-specific tissue regeneration. Importantly, our approach provides a flexible and robust platform that has generated multiple human antibodies that possess either tissue, disease or cell selectivity. We have developed two technologies to modulate the Wnt pathway; Wnt-mimetics (SWAP) and R-spondin-mimetics (SWEETS).
SWAP (Surrozen Wnt signal activating proteins) are designed to mimic the activity of Wnt protein. They are bi-specific full-length human (IgG) antibodies that, like Wnt proteins, directly activate the canonical Wnt-signaling pathway in target tissue. We have established a robust SWAP discovery platform and generated and validated a broad library of SWAPs that have successfully activated Wnt-signaling in vivo.
SWEETS (Surrozen Wnt signal enhancer engineered for tissue specificity) are designed to enhance the body’s response to endogenous, or existing, Wnt protein. They are antibody-based molecules that, like R-spondin, enhance Wnt signaling by stabilizing Frizzled receptors. We have established a robust SWEETS discovery platform and generated hepatocyte-specific SWEETS.